Anti-Aflibercept (EYLEA) Quantitative ELISA Assay Kit
The Anti-Aflibercept (EYLEA) Quantitative ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Sensitivity: 1 ng/mL
Standard Range: 0 – 300 ng/ml
Incubation Time: 1 hour 50 minutes
Sample Type: Serum, Plasma
Sample Size: 50 µL
Alternative Name: Eylea
Assay Background for Adalimumab Assay
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fe region of human immunoglobulin gamma 1 (IgG1). Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Compared to other anti-VEGF drugs like bevacizumab and ranibizumab, aflibercept has a higher binding affinity to VEGF-A.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the drug Aflibercept. After incubation, the wells are washed. Then, horse radish-peroxidase (HRP) conjugated probe is added and binds to Aflibercept antibodies captured by the drug Aflibercept on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of Aflibercept antibodies in the sample or standard. Results of samples can be determined directly using the standard curve.
Related Products
Aflibercept (EYLEA) ELISA Assay Kit
High Sensitive Aflibercept (EYLEA) ELISA Assay Kit
Anti-Aflibercept (EYLEA) Qualitative ELISA Assay Kit
